NIROPHARM CORPORATE PROFILE

NIROPHARM, the Umbrella Body of Nigerian Representatives of Overseas Pharmaceutical Manufacturers with a distinctive Research and Development Orientation encompasses a wide variety of pharmaceutical marketing companies, but all with a common trait of representing one or many overseas pharmaceutical manufacturers.

NIROPHARM MEMBER COMPANIES: Member Companies (those with online presence  can be selected to visit the company's corporate Web pages) include:

Biofem Pharmaceuticals Ltd, Bolar Pharmaceuticals Ltd, Chi Pharmaceuticals Ltd, Cipla Evans, Coriander Resources Limited, Crystal Foods & Drugs Limited, Dafra Pharma Limited, Dortemag, F.A.B Medicals Limited, Fidson, GSK, Janssen Cilag, JB Pharmaceuticals Limited, Korlyns Pharmaceuticals Ltd, Labyrinth, May & Baker Nigeria Plc, Megalife Sciences, Miraflash Nig Limited, Novartis, Nutrihealth, OBJ Pharmaceuticals Ltd, Oculus, Olpharm, Onifam Laboratories Limited, Pfizer, Reals Pharmaceuticals Ltd (AstraZeneca), Rodot, Rufus Obi Chemists & Co Ltd, Sanofi, Sequoia Pharma Limited, Solidum Pharmaceuticals Ltd, Swipha, Synergy, Taylek Drugs Company Limited, United African Laboratory Limited, Uripharma, Zoomota.

As more companies register under the organization, this member list will be updated.

Membership Criteria

• Subsidiary of or a valid Power of Attorney from research based Reputable Overseas Pharmaceutical Manufacturer
• Core portfolio of patent protected products
• Evidence of Registration with PCN
• Evidence of Product Registration with NAFDAC

Download Membership Form here visit the Members page for a brief profile of each member company and online contact.

 Nigeria Pharma industry Overview

• Market Size: $218m (source BMI monitor, 2006)
• Imports: 70%
• Local Manufacture: 30%

NIROPHARM is dedicated to working to improve and enhance the quality of service to the Nation, public (local and internationa) Image and the scope of the Nigerian Pharmaceutical Industry who face a number of challenges. Some of the challenges that NIROPHRM is set  to tackle with all the resources it has at its disposal include: 

• High cost of funds
• Poor infrastructure
• Poor IPR protection
• Chaotic drug distribution
• Lack of data for planning
• High level of Counterfeiting
• Low capacity of Regulatory Agencies
• Regulatory Agency, not computerized
• Poor surveillance particularly at the land borders

A brief profile about the individual member companies can be found here in the Member area.